1025720-94-8

Basic information

• Product Name: N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
• Synonyms: N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide;N-[4-[(2-amino-3-chloro-4-pyridinyl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-3-pyridinecarboxamide;N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide BMS 777607;BMS777607 (ASLAN-002);ASLAN-002;N-(4-((2-Amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2;EOS-60544
• CAS NO: 1025720-94-8
• Molecular Formula: C₂₅H₁₉ClF₂N₄O₄
• Molecular Weight: 512.8925664
• Product Categories: Inhibitors
• Mol File: 1025720-94-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 667.9±55.0 °C(Predicted)
• Appearance: /
• Density: 1.49
• Solubility: ≥25.65 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
• PKA: 10.54±0.70(Predicted)
• CAS DataBase Reference: N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide(1025720-94-8)
• EPA Substance Registry System: N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide(1025720-94-8)

Safety Data

• Hazardous Substances Data: 1025720-94-8(Hazardous Substances Data)

Usage

Description

N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is a complex organic compound with a unique chemical structure. It is characterized by its fluorophenyl and pyridine moieties, which contribute to its biological activity and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is used as a selective and orally efficacious inhibitor of the Met Kinase superfamily for the treatment of various diseases. Its application in this industry is due to its ability to selectively target and inhibit the Met Kinase superfamily, which plays a crucial role in cell growth, proliferation, and survival, and is often dysregulated in various diseases, including cancer.
Used in Cancer Research:
In the field of cancer research, N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is used as a potential therapeutic agent for the treatment of cancer. Its application in this field is based on its ability to inhibit the Met Kinase superfamily, which is often overactivated in various types of cancer, leading to uncontrolled cell growth and tumor progression.
Used in Drug Development:
N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is also used in drug development as a lead compound for the design and synthesis of novel inhibitors targeting the Met Kinase superfamily. Its application in this field is due to its structural features and biological activity, which make it a promising starting point for the development of new drugs with improved potency, selectivity, and pharmacokinetic properties.

Biological Activity

bms 777607 is a novel, selective and orally available atp-competitive met kinase inhibitor that primarily targets several met family members, including ron, met, tyro-3 and axi, with half maximal inhibitory concentration ic50 of 1.8 nmol/l, 3.9 nmol/l, 4.3 nmol/l and 1.1 nmol/l respectively. moreover, at higher concentrations, bms 777607 has been found to inhibit other protein tyrosine kinases, including mer, flt-3, aurora b, lck and vegfr2 with ic50 of 14 nmol/l, 16 nmol/l, 78 nmol/l, 120 nmol/l and 180 nmol/l respectively. in previous studies, bms 777607 potently inhibited the auto-phosphorylation of c-met (ic50: 20 nmol/l) leading to impaired xenograft growth.small-molecule inhibitor bms-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. mol cancer ther. 2013 may;12(5):725-36. doi: 10.1158/1535-7163.mct-12-1079. epub 2013 mar 6.

references

[1]dai y, siemann dw. bms-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. mol cancer ther. 2010 jun;9(6):1554-61. doi: 10.1158/1535-7163.mct-10-0359. epub 2010 jun 1.[2]sharma s, zeng jy, zhuang cm, zhou yq, yao hp, hu x, zhang r, wang mh.

Upstream product

• 403-19-0 2-fluoro-4-nitrophenol 
• 1415797-76-0 3-chloro-4-(2-fluoro-4-nitrophenyloxy)pyridine-2-amine 
• 1203499-43-7 tert-butyl (3,4-dichloropyridin-2-yl)carbamate 
• 1401415-16-4 4-(4-amino-2-fluorophenyloxy)-3-chloropyridine-2-amine 
• 64-17-5 ethanol 
• 1025721-12-3 3-chloro-4-(2-fluoro-4-(1-(4-fluorophenyl)-4-iodo-2-oxo-1,2-dihydropyridine-3-carboxamido)phenoxy)-picolinamide 
• 1025721-21-4 1-(4-fluoro-phenyl)-4-iodo-2-oxo-1,2-dihydro-pyridine-3-carbonyl chloride 
• 1025721-10-1 1-(4-fluoro-phenyl)-4-iodo-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid 
• 1025721-07-6 1-(4-fluorophenyl)-4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde 
• 726206-53-7 4-iodo-2-oxo-1,2-dihydropyridine-3-carbaldehyde 
• 158669-26-2 4-iodo-2-methoxynicotinaldehyde 
• 1025721-01-0 4-(4-amino-2-fluorophenoxy)-3-chloropyridine-2-carboxamide 
• 1025720-99-3 3,4-dichloropyridine-2-carboxamide 
• 959578-03-1 3,4-dichloropyridine-2-carboxylic acid 

Relevant articles and documents

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

PYRIDINONE COMPOUNDS

The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as ca